Accelerated Hypofractionated Radiotherapy and Concurrent Etoposide/Cisplatin in Patients with Limited-Disease SCLC (LD-SCLC)

• 作者: Ali Azmy Iman Fouad Sherif Abdelwahab Wessam Elghamry Zeinab Elsayed
• 来源期刊: 癌症治疗(英文)
• 学科: 医学
• 关键词: LD-SCLC ETOPOSIDE CISPLATIN Accelerated Radiation Therapy
• 年，卷（期）: 2020,（11）
• 页码范围: 683-694
• 页数: 12页
• 分类号: R73

摘要

<strong>Background</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><strong>: </strong></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The optimal TRT dose/fraction for LD-SCLC remains debatable, and due to increasing number of population in Egypt and number of patients as well, so reducing the duration of radiation therapy is favored. This study was conducted using etoposide and cisplatin (EP) concurrently with accelerated hypofractionated TRT to evaluate the response and toxicity of this protocol in the treatment of patients with limited-disease small cell lung cancer (LD-SCLC).</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">Patients and Methods</span></b></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><b><span style="font-family:Verdana;">: </span></b></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">Thirty patients with previously untreated LD-SCLC were enrolled into this study between June 2012 and February 2015. All patients received etoposide 100 mg/m</span>^{<span style="font-family:Verdana;">2</span>}<span style="font-family:Verdana;"> days 1 to 3 and cisplatin 25 mg/m</span>^{<span style="font-family:Verdana;">2</span>}<span style="font-family:Verdana;"> days 1 to 3 with start of accelerated hypofractionated thoracic radiation therapy on first day of the second cycle of chemotherapy of 55 Gy,</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">2.5 Gy/fraction over 30 days. Chemotherapy was given 4</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="fon